SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors
SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR...
Transforming Healthcare with AI: YiduTech’s Gong Rujing at Summer Davos
DALIAN, China, July 1, 2024 /PRNewswire/ -- "AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New Champions, also known as Summer Davos, in Dalian, Ms. Gong Rujing (Yingying), Chairwoman and Founder of...
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
HONG KONG, June 31, 2024 /PRNewswire/ -- Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The management provided detailed explanations on the key performance highlights, development strategies, and future outlook. Owing...
CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products
The deal leverages CBC's hands-on "investor-operator" approach to accelerate portfolio companies' asset acquisition and strategic international expansion SINGAPORE, July 1, 2024 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its controlled portfolio company, Hasten Biopharmaceutical ("Hasten"), an innovation-driven biopharmaceutical company, has successfully acquired the asset rights of 14 branded products across...
Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.
CASTRES, France, June 28, 2024 /PRNewswire/ -- The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients* in Europe. In 2022, Pierre Fabre Laboratories acquired the exclusive license...
Comprehensively Covering Multiple Myeloma: IASO Bio’s GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by...
DPC Dash – Domino’s Pizza China Expansion Hits 900 Stores in Mainland China
HONG KONG, June 28, 2024 /PRNewswire/ -- DPC Dash Ltd -Domino's Pizza China ("DPC Dash" or the "Company") (1405.HK), Domino's Pizza's exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the Macau Special Administrative Region of China, today celebrated the grand opening of its 900th...
Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area
SHANGHAI, June 28, 2024 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. (referred to as "Hasten") announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company. According to the agreement, Hasten will also own the Marketing Authorization Holder (MAH) rights for these products in 8...
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group has completed STP707 Phase I clinical study with strong safety profile and stable disease activity for treatment of...
Natalia Vodianova Invests in Swiss Beauty and Longevity Brand NIANCE
ZURICH, June 28, 2024 /PRNewswire/ -- Swiss Health & bioBeauty AG, owner of the prestigious beauty and longevity brand NIANCE, announces that internationally renowned supermodel, philanthropist, and investor Natalia Vodianova has become one of the key shareholders of NIANCE. This strategic partnership marks a significant milestone in the brand's journey towards global prominence. About NIANCE NIANCE is a...
